Focus Partners Advisor Solutions LLC Increases Stock Position in Becton, Dickinson and Company $BDX

Focus Partners Advisor Solutions LLC raised its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 42.3% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,500 shares of the medical instruments supplier’s stock after buying an additional 1,337 shares during the period. Focus Partners Advisor Solutions LLC’s holdings in Becton, Dickinson and Company were worth $775,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Saudi Central Bank purchased a new stake in Becton, Dickinson and Company during the 1st quarter valued at $26,000. Smallwood Wealth Investment Management LLC purchased a new stake in Becton, Dickinson and Company during the 1st quarter valued at $27,000. Cornerstone Planning Group LLC boosted its position in Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 99 shares during the period. Kelly Lawrence W & Associates Inc. CA purchased a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth about $31,000. Finally, WPG Advisers LLC purchased a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth about $36,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on BDX shares. Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Morgan Stanley raised their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Argus raised their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Piper Sandler reaffirmed a “neutral” rating and issued a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $205.40.

Becton, Dickinson and Company Stock Down 1.4%

Shares of Becton, Dickinson and Company stock opened at $184.35 on Wednesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The company has a 50-day moving average of $189.49 and a 200 day moving average of $183.53. The firm has a market cap of $52.84 billion, a price-to-earnings ratio of 33.16, a PEG ratio of 1.46 and a beta of 0.25. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The company had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders have sold 1,895 shares of company stock worth $358,995. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.